[December 22, 2014]

INVESTOR ALERT: Investigation of Roka Bioscience, Inc. Announced by Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Roka Bioscience, Inc. ("Roka" or the "Company") (NASDAQ:ROKA) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by Roka concerning the Company's business and financial prospects.

Please contact Lesley Portnoy at (310) 201-9150, or at [email protected] to discuss this matter. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

Roka is a molecular diagnostics company focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens in the United State. The Company's Atlas instrument is a fully automated molecular diagnostic testing instrument for high-volume foodborne pathogen testing laboratories. The investigation is related to the Company's November 6, 2014, announcement of Roka's third quarter 2014 financial results, including a net loss for the third quarter of $0.64 per share. According to the Company, there were no new placements of Atlas instruments during the quarter.

Following this news, Roka shares declined approximately 64%, or $5.34 per share, to a closing price of $3.00 per share on November 7, 2014, on extremely heavy volume. Roka shares traded as high as $13 per share as recently as July 18, 2014 - one day after the Company's initial public offering on July 17, 2014.

If you purchased Roka shares, if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at (310) 201-9150, Toll Free at (888) 773-9224, by e-mail to [email protected], or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

[ Back To TMCnet.com's Homepage ]